Petros Pharmaceuticals, Inc. Increase (Decrease) in Inventories
Petros Pharmaceuticals, Inc. (PTPI) reported Increase (Decrease) in Inventories of -$307.59 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2025-03-31
- Petros Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2024-12-31 was -$67.80K.
- Petros Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2024-09-30 was -$70.62K, a 173.21% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2024-06-30 was -$128.62K.
- Petros Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2024-03-31 was -$40.56K, a 173.62% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2024 was -$307.59K.
- Petros Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2023 was -$273.61K, a 132.76% decline from fiscal 2022.
- Petros Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2022 was $835.32K.
- Petros Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2021 was -$412.74K.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$67.80K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$138.42K derived: sum of 2 quarters · filed 2025-03-31 | -$267.04K derived: sum of 3 quarters · filed 2025-03-31 | -$307.59K 10-K · filed 2025-03-31 |
| 2024-09-30 | -$70.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$199.24K derived: sum of 2 quarters · filed 2024-11-13 | -$239.79K 10-Q · filed 2024-11-13 | -$576.60K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | -$128.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$169.18K 10-Q · filed 2024-08-14 | -$505.98K derived: sum of 3 quarters · filed 2025-03-31 | -$409.52K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | -$40.56K 10-Q · filed 2024-05-15 | -$377.36K derived: sum of 2 quarters · filed 2025-03-31 | -$280.90K derived: sum of 3 quarters · filed 2025-03-31 | -$369.26K derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | -$336.80K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$240.34K derived: sum of 2 quarters · filed 2025-03-31 | -$328.70K derived: sum of 3 quarters · filed 2025-03-31 | -$273.61K 10-K · filed 2025-03-31 |
| 2023-09-30 | $96.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $8.10K derived: sum of 2 quarters · filed 2024-11-13 | $63.19K 10-Q · filed 2024-11-13 | -$721.19K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$88.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$33.27K 10-Q · filed 2024-08-14 | -$817.64K derived: sum of 3 quarters · filed 2024-08-14 | -$572.30K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $55.09K 10-Q · filed 2024-05-15 | -$729.28K derived: sum of 2 quarters · filed 2024-05-15 | -$483.94K derived: sum of 3 quarters · filed 2024-05-15 | -$536.41K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$784.38K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$539.03K derived: sum of 2 quarters · filed 2024-04-01 | -$591.50K derived: sum of 3 quarters · filed 2024-04-01 | $835.32K 10-K · filed 2024-04-01 |
| 2022-09-30 | $245.34K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-15 | $192.88K derived: sum of 2 quarters · filed 2023-11-15 | $1.62M 10-Q · filed 2023-11-15 | $1.57M derived: sum of 4 quarters · filed 2023-11-15 |
| 2022-06-30 | -$52.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.37M 10-Q · filed 2023-08-14 | $1.32M derived: sum of 3 quarters · filed 2023-08-14 | $1.67M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.43M 10-Q · filed 2023-05-15 | $1.38M derived: sum of 2 quarters · filed 2023-05-15 | $1.72M derived: sum of 3 quarters · filed 2023-05-15 | $1.21M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$51.46K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | $297.75K derived: sum of 2 quarters · filed 2023-03-31 | -$218.76K derived: sum of 3 quarters · filed 2023-03-31 | -$412.74K 10-K · filed 2023-03-31 |
| 2021-09-30 | $349.21K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-15 | -$167.29K derived: sum of 2 quarters · filed 2022-11-15 | -$361.28K 10-Q/A · filed 2022-11-15 | -$524.08K derived: sum of 4 quarters · filed 2022-11-15 |
| 2021-06-30 | -$516.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$710.50K 10-Q · filed 2022-08-12 | -$873.30K derived: sum of 3 quarters · filed 2022-08-12 | -$1.06M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$193.99K 10-Q · filed 2022-05-16 | -$356.79K derived: sum of 2 quarters · filed 2022-05-16 | -$540.78K derived: sum of 3 quarters · filed 2022-05-16 | -$696.76K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$162.80K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$346.79K derived: sum of 2 quarters · filed 2022-03-31 | -$502.78K derived: sum of 3 quarters · filed 2022-03-31 | -$728.29K 10-K · filed 2022-03-31 |
| 2020-09-30 | -$183.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$339.98K derived: sum of 2 quarters · filed 2021-11-15 | -$565.49K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$155.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$381.49K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$225.51K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |